๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)
NCT07160647dMMR/MSI-H-type Rectal Adenocarcinoma
Sir Run Run Shaw Hospital
Phase 2
29
Hangzhou
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 2
218
Yangzhou, Tianjin, Hangzhou, Huaian, Shanghai
2025-08-19
Recruiting
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650Diffuse Large B-Cell Lymphoma
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Recruiting
EUS-PPG Alteration After Ligation and Sclerotherapy in Esophageal Varices
NCT07253090Esophagogastric Varices
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
70
Hangzhou
2025-08-18
By invitation
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT07376629TNBC
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Recruiting
The Treatment Outcomes of Cesarean Scar Pregnancy
NCT07608094Cesarean Scar Pregnancy
Women's Hospital School Of Medicine Zhejiang University
Observational
82
Hangzhou
2025-08-13
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
BioNTech SE
Phase 1/2
1,438
Hangzhou, Tianjin, Wuhan
2025-08-12
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
Novartis Pharmaceuticals
Phase 2
407
Hangzhou, Shanghai
2025-08-07
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Active, closed
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
NCT07142421Esophageal Squamous Cell Carcinoma (ESCC)
First Affiliated Hospital of Zhejiang University
Phase 2
35
Hangzhou
2025-08-06
Recruiting
A Single-Center Clinical Study on the Efficacy and Safety of VISOR
NCT07071948Urolithiasis, Calcium Oxalate, Kidney Stone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
20
Hangzhou
2025-08-06
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Active, closed
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633Hepatocellular Carcinoma
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
NCT07391839Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
Suzhou Mednovo Yi Medical Technology Co., Ltd.
Phase 1
40
Hefei, Fuzhou, Guangzhou, Nanjing, Jinan, Hangzhou, Henan, Shanghai
2025-08-04
Recruiting
Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
NCT07104214Gastric Cancer Stage, Esophageal Cancer, Gastroparesis
Zhejiang University
Observational
5,000
Hangzhou, Jiaxing, Lishui
2025-08-03
Not yet open
Smartphone Multimodal Health Intervention for Neurological Enhancement (SHINE)
NCT07092371Cognitive Impairment, Dementia, Artificial Intelligence (AI), Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,036
Hangzhou
2025-08-01
Recruiting
Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival
NCT07813208Acute Lymphoblastic Leukemia, Pediatric
The Children's Hospital of Zhejiang University School of Medicine
Observational
500
Hangzhou
2025-08-01
Active, closed
Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels
NCT07342712Myelofibrosis
First Affiliated Hospital of Zhejiang University
Observational
40
Hangzhou
2025-08-01
Not yet open
29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
NCT07100236Primary Hepatocellular Carcinoma
Junjie Xu
Observational
350
Hefei, Chaoyang, Fuzhou, Guangzhou, Zhengzhou, Shanghai, Hangzhou, Wenzhou
2025-08-01
Recruiting
A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer
NCT07304934Breast Cancer, Axillary Lymph Node Metastasis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
400
Hangzhou
2025-08-01
Not yet open
The Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease
NCT06713694Inflammatory Bowel Disease (IBD), Cognitive Behavior Therapy
Wang Zhen
Not applicable
40
Hangzhou
2025-08-01
Recruiting
Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
NCT07123545Advanced Hepatocellular Carcinoma (HCC)
Zhejiang University
Phase 1/2
20
Hangzhou
2025-08-01
Not yet open
Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
NCT07023575Interstitial Lung Abnormalities
China-Japan Friendship Hospital
Observational
100,000
Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang
2025-08-01
Recruiting
Personalized Prevention and Treatment Strategies for Adolescent Idiopathic Scoliosis Via a Comprehensive Health Management Platform
NCT06314594Adolescent Idiopathic Scoliosis (AIS)
Hangzhou Medical College
Not applicable
76
Hangzhou
2025-08-01
Recruiting
Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
NCT07105579Leukemia, Relapse
First Affiliated Hospital of Zhejiang University
Phase 2
31
Hangzhou
2025-08
Not yet open
Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion
NCT07114107Atopic Rhinitis, Atopic Asthma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou
2025-08
Not yet open
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer๏ผˆmCRPC๏ผ‰
NCT07104643mCRPC
TYK Medicines, Inc
Phase 1/2
48
Hangzhou
2025-08
Not yet open
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer๏ผˆmCRPC๏ผ‰
NCT07104617Metastatic Castration-resistant Prostate Cancer (mCRPC)
TYK Medicines, Inc
Phase 1/2
48
Hangzhou
2025-08
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension
NCT07080697Acute Necrotizing Pancreatitis, Portal Hypertension
Zhejiang University
Not applicable
66
Hangzhou
2025-07-30
Recruiting
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke
NCT07047014Stroke, Ischemic, Medium Vessel Occlusions
Beijing Tiantan Hospital
Phase 3
596
Beijing, Jiuquan, Shijiazhuang, Jiyuan, Lingbao, Nantong, Hangzhou
2025-07-30
Recruiting
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
NCT07022002Locally Advanced, Recurrent or Metastatic Malignancies
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2
340
Hangzhou
2025-07-30
Recruiting
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT07061535Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Changsha, Jinan, Hangzhou
2025-07-30
Recruiting
A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China
NCT07082530Cesarean Delivery
Women's Hospital School Of Medicine Zhejiang University
Not applicable
1,074
Hangzhou
2025-07-30
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
AbbVie
Phase 3
120
Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou
2025-07-28
By invitation
Robotic Arm-assisted THA Vs. Conventional THA in Legg-Calvรฉ-Perthes Disease
NCT07122323Legg-Calvรฉ-Perthes Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
50
Hangzhou
2025-07-28
Not yet open
Individualized Location-based rTMS for Migraine Treatment: A Multicenter Clinical Study
NCT07086274Migraine, Transcranial Magnetic Stimulation Repetitive
First Affiliated Hospital of Zhejiang University
Not applicable
152
Hangzhou
2025-07-25
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment
NCT07090759Chronic Hepatitis b
Fujian Akeylink Biotechnology Co., Ltd.
Phase 3
526
Hangzhou
2025-07-24
Recruiting
Modified Diagnosis and Treatment of Neonatal Hemolysis With ETCOc in sNH
NCT06832800Neonatal Hyperbilirubinemia
Women's Hospital School Of Medicine Zhejiang University
Phase EARLY_PHASE1
250
Hangzhou
2025-07-21
Not yet open
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
NCT07068516Gastric Cancer Stage
Xiangdong Cheng
Phase 3
470
Hangzhou
2025-07-20
Active, closed
Study on the Application of Adaptive Fluidics Technology in Lens Diseases Surgery
NCT07062107Lens Diseases
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
320
Hangzhou
2025-07-20
By invitation
Safety and Efficacy of Chocolate Balloon Catheter in Peripheral Arterial Disease (CHOCO-PAD)
NCT06933992Peripheral Arterial Disease
First People's Hospital of Hangzhou
Observational
171
Hangzhou
2025-07-20
Not yet open
Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
NCT07074353Locally Advanced Rectal Cancer
Zhejiang Cancer Hospital
Phase 3
360
Hangzhou
2025-07-20
Recruiting
REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy
NCT07006493Hypertrophic Cardiomyopathy, Obstructive
SuZhou Sinus Medical Technologies Co.,Ltd
Not applicable
124
Beijing, Hangzhou
2025-07-20
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
NCT07005713Chronic Spontaneous Urticaria
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168Acute Myeloid Leukemia, Leukemia
Daiichi Sankyo
Phase 2
130
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao
2025-07-18
Recruiting
Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD
NCT07153692Parkinson's Disease and Parkinsonism, Dysphagia
Wang Ping
Not applicable
58
Hangzhou
2025-07-17
Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07069712Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2
100
Beijing, Changchun, Changzhi, Chengdu, Fuzhou, Hangzhou, Kunming, Qingdao
2025-07-17
Recruiting
Clinical Study of Acupoint Application on Relieving qi Deficiency and Constipation in Patients Undergoing Chemotherapy
NCT07276932Postoperative Chemotherapy, Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
106
Hangzhou
2025-07-16
Recruiting
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07039669Pulmonary Disease, Chronic Obstructive (COPD)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
594
Beijing, Shenzhen, Nanjing, Hangzhou
2025-07-16
Recruiting
A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors
NCT07092748Advanced Solid Cancers
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 1
110
Hangzhou
2025-07-15
Recruiting
Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules
NCT07114120Bronchiectasis, COPD
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
214
Hangzhou, Huzhou, Jinhua, Yueqing, Zhoushan
2025-07-14
Recruiting
The Impact of the Adequacy of Keratinized Mucosa on Peri-implant Tissue Health and Patient-reported Outcomes
NCT07124416Edentulous Alveolar Ridge
The Dental Hospital of Zhejiang University School of Medicine
Observational
150
Hangzhou
2025-07-10
Recruiting
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT06953323Advanced Solid Tumor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Not yet open
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
NCT07032324B-Cell Non-Hodgkin Lymphoma
Qian Wenbin
Phase 1
27
Hangzhou
2025-07-08
Active, closed
Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects
NCT07799025Healthy Volunteers
Shanghai Minwei Biotechnology Co., Ltd
Phase 1
54
Hangzhou
2025-07-07
Recruiting
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
Sanofi
Phase 2
99
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
NCT07105852Cholangiocarcinoma
Sir Run Run Shaw Hospital
Phase 2
59
Hangzhou
2025-07-03
Recruiting
Post-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in China
NCT07025304Nasal Obstruction Due to Inferior Turbinate Hypertrophy
Smith & Nephew, Inc.
Not applicable
105
Guangzhou, Zhengzhou, Nanjing, Changchun, Hangzhou
2025-07-02
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Phase 3
1,750
Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou
2025-07-02
Recruiting
RAB Versus Ultrathin Bronchoscopy With VBN in the Diagnosis of PPNs
NCT06962436Peripheral Pulmonary Nodules
Shanghai Chest Hospital
Not applicable
186
Jinan, Shanghai, Hangzhou
2025-07-02
Not yet open
Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol
NCT06990854Postherpetic Neuralgia ( PHN )
Dexiong Han
Not applicable
207
Hangzhou
2025-07-01
Recruiting
18F-Pentixafor PET in Hematologic Malignancies
NCT07122674Hematological Malignancies
First Affiliated Hospital of Zhejiang University
Observational
100
Hangzhou
2025-07-01
Recruiting
Epidural Electrical Stimulation in Spinal Cord Injury (T11-L3)
NCT07207798Spinal Cord Injuries (SCI)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
10
Hangzhou
2025-07-01
Active, closed
18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC
NCT07449858Non Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Guangzhou, Shenyang, Chengdu, Hangzhou
2025-07-01
Active, closed
VAP-Measured Lipid Subfractions and In-Stent Restenosis After PCI
NCT07533656In-Stent Restenosis, Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,600
Hangzhou
2025-07-01
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Recruiting
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
NCT07073833Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1
40
Hangzhou, Shanghai
2025-07-01
Recruiting
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NCT07068542Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
Zhejiang Provincial People's Hospital
Not applicable
94
Hangzhou
2025-07-01
Not yet open
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
NCT07038460Resectable Non-small Cell Lung Cancer
Wen-zhao ZHONG
Phase 2
134
Guangzhou, Changsha, Hangzhou
2025-07
Active, closed
A Study on Bioequivalence of Cabergoline Tablets in Human Body
NCT07008417Hyperprolactinemia
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
72
Hangzhou
2025-06-30
Recruiting
Comparison of Different Pulsed Field Ablation Catheters in Atrial Fibrillation
NCT07036965Atrial Fibrillation (AF)
Hangzhou Dinova EP Technology Co., Ltd
Not applicable
292
Hangzhou
2025-06-30
By invitation
Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
NCT07023965Peripheral Arterial Disease(PAD), Arterial Occlusive Disease, Arteriosclerosis Obliterans, Thromboangiitis Obliterans
Beijing Northland Biotech. Co., Ltd.
Observational
542
Beijing, Chifeng, Dalian, Hangzhou, Xi'an
2025-06-30
Recruiting
Effectiveness of DITM Versus IMT in COPD Patients
NCT06958666COPD (Chronic Obstructive Pulmonary Disease)
Sir Run Run Shaw Hospital
Not applicable
410
Hangzhou, Lishui, Taizhou
2025-06-30
Recruiting
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
NCT07071090Solid Tumor Malignancies
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
By invitation
A Study on the Efficacy of Environmental Probiotics in Patients With Cat Hair Allergies
NCT07114133Cat Allergy (Disorder), Allergic Rhinitis, Allergic Asthma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2025-06-30
Recruiting
A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
NCT07039201Advanced Hepatocellular Carcinoma (HCC)
Zhejiang University
Not applicable
12
Hangzhou
2025-06-28
Active, closed
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
NCT06843408Chronic Graft-versus-host-disease
Incyte Corporation
Phase 1/2
32
Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan
2025-06-25
Recruiting
The Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy
NCT07049094Brain Tumor Adult, Cerebrovascular Disease
Zhejiang University
Phase 4
218
Hangzhou
2025-06-25
Recruiting
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
NCT06959095Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 3
981
Changsha, Chengdu, Guangzhou, Hangzhou, Jiangmen, Jiangxi, Mianyang, Qingyuan
2025-06-20
Recruiting
A Study in Children With Achondroplasia
NCT07301463Achondroplasia
Abbisko Therapeutics Co, Ltd
Observational
260
Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou
2025-06-20
Not yet open
Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
NCT07035860Carbon Ion Radiotheray
Ji Yongling
Observational
34
Hangzhou
2025-06-16
Recruiting
A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
NCT07193641Non Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-06-15
Recruiting
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
NCT06990698Advanced Solid Tumors
Zhuhai Fapon Biopharma Co., Ltd.
Phase 1
108
Wuhan, Taiyuan, Hangzhou
2025-06-12
Recruiting
COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients
NCT07012772Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis, Cholelithiasis
Zhejiang University
Phase 2
50
Hangzhou
2025-06-12
Recruiting
Feasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study
NCT07051980Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis, Cholelithiasis
Zhejiang University
Phase 2
50
Hangzhou
2025-06-12
Recruiting
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
NCT06892145Systemic Lupus Erythematosus (SLE), Refractory
Chongqing Precision Biotech Co., Ltd
Phase 1
12
Hefei, Hangzhou
2025-06-12
Recruiting
Leucine Plus Radiochemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
NCT07359989Rectal Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
33
Hangzhou
2025-06-11
Recruiting
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
NCT06953999Pancreatic Cancer
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Recruiting
Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial
NCT07021534Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments
Zhejiang University
Phase 1
12
Hangzhou
2025-06-10
Recruiting
Protein Supplementation Intervention on Body Weight
NCT06989203Obesity, Weight Loss, Protein Supplementation
Chinese Academy of Sciences
Not applicable
140
Hangzhou
2025-06-10
Recruiting
Probiotic Intervention on Body Weight
NCT06989177Obesity, Homeostasis, Weight Loss, Probiotic Intervention
Chinese Academy of Sciences
Not applicable
140
Hangzhou
2025-06-10
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
Merck Sharp & Dohme LLC
Phase 2
149
Guangzhou, Changsha, Changchun, Shanghai, รœrรผmqi, Hangzhou
2025-06-09
Recruiting
The AIRTIVITYโ„ข Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984Agitation, Alzheimer Disease
Celgene
Phase 2
120
Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou
2025-06-09
Rows per page Showing 601–700 of 1812
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=7

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.